BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 77.79 USD -0.03% Market Closed
Market Cap: $15B

Wall Street
Price Targets

BBIO Price Targets Summary
BridgeBio Pharma Inc

Wall Street analysts forecast BBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BBIO is 90.56 USD with a low forecast of 68.11 USD and a high forecast of 115.5 USD.

Lowest
Price Target
68.11 USD
12% Downside
Average
Price Target
90.56 USD
16% Upside
Highest
Price Target
115.5 USD
48% Upside
BridgeBio Pharma Inc Competitors:
Price Targets
FATE
Fate Therapeutics Inc
286% Upside
8841
TOC Co Ltd
28% Upside
NCSM
NCS Multistage Holdings Inc
27% Upside
RLMD
Relmada Therapeutics Inc
157% Upside
VINP
Vinci Partners Investments Ltd
10% Upside
OFIX
Orthofix Medical Inc
73% Upside
HOTH
Hoth Therapeutics Inc
348% Upside
ONDS
Ondas Holdings Inc
0% Upside

Revenue
Forecast

N/A
Past Growth
79% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
79% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 4 years is 79%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BBIO's stock price target?
Price Target
90.56 USD

According to Wall Street analysts, the average 1-year price target for BBIO is 90.56 USD with a low forecast of 68.11 USD and a high forecast of 115.5 USD.

What is BridgeBio Pharma Inc's Revenue forecast?
Projected CAGR
79%

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 4 years is 79%.

Back to Top